Anti-Infectives Rx
Date: Location: Cost:
September 19, 2017 Harvard Medical School - Joseph B. Martin Conference Center
77 Avenue Louis Pasteur
Boston, MA 02115
Location >

Starting at $1950

 

Dress Code:
Business Attire

Register

ANTI-INFECTIVES RX - SEPTEMBER 19, 2017 - DRAFT

Speakers and Co-hosts include: 
Cara Cassino, Rita Colwell, Ryan Davies, Shalabh Gupta, Charlotte Hubbert, Evan JonesJeff Riley, Rene Russo, James Sapirstein, Marco Taglietti, Ramani Varanasi

Time Agenda
7:30-8:30 am

Registration and Networking Breakfast

8:30-8:45 am

Welcome and Opening Remarks

8:45-9:15 am

Tackling Resistance: The Promise and The Challenge
Nicholas BenedictCEO, Allecra Therapeutics; Ryan Davies, CEO, Curza; Steven Gelone, CSO, Head, BD, Nabriva; Evan JonesChairman & CEO, OpGen; Jeff Riley, CEO, Synthetic Biologics

9:15-9:45 am

Fostering Innovation via Partnerships and Deals
Martin Driscoll, CEO, Spring Bank Pharmaceuticals; Charlotte HubbertPartner, Bill & Melinda Gates Foundation; Laurence ReidCEO, Warp Drive Bio; Frederick Sweeney, VP, BD & Strategic Alliances, bioMerieux; Ramani Varanasi, President & CEO, X-Biotix Therapeutics

9:45-10:05 am

Fireside Chat

10:05-10:30 am

Networking Break

10:30-11:00 am

Innovation versus Pricing: Maintaining Cost Efficacy for Treatments
Laurenz KellenbergerCSO, Basilea Pharmaceutica; Will Lewis, CEO, Insmed; Andrew Rae, CEO, iCO Therapeutics

11:00-11:30 am

Progress Towards Curative Therapies
Francisco Diaz-Mitoma, CMO, VBI Vaccines; James Sapirstein, CEO, Contravir Pharmaceuticals; JoAnn Suzich, VP, Research, MedImmune

11:30-12:00 pm

Enhancing Treatments for Rare and Infectious Diseases

Enhancing Treatments for Rare and Infectious Diseases
12:00-1:00 pm

Networking Lunch

1:00-1:30 pm

Regulatory Challenges: Expanding Endpoints
David MantusCDO, Arsanis; Antony Pfaffle, CSO, CorMedix
Moderator: Marco TagliettiCEO, Scynexis

1:30-2:00 pm

Enhancing Treatment in Emerging Markets 
David Friend,
CSO, Evofem Biosciences; Shalabh Gupta, President & CEO, Globavir 

2:00-2:30 pm

Advances Against Rare and Resistant Pathogens
Marc Gitzinger, CEO, BioVersys; Gregory Mario, President & CEO, Taxis Pharmaceuticals; Malcom Thomas, CEO, Agile Sciences; Jeff WagerCEO, EnBiotix; Zachary ZimmermanCEO, Forge Therapeutics

2:30-2:50 pm

Bench to Bedside Keynote
Rita ColwellFormer Director, National Science Foundation

2:50-3:20 pm

Networking Break

3:20-3:50 pm

The New Wave of Anti-Infectives: MicroBiome & Immunotherapy
Steven Gilman, Chairman, ContraFect; Alex Huang, CEO, Quellthera; Lee Jones, President & CEO, Rebiotix; Deborah O'Neil, CEO, NovaBiotics; Rene Russo, President & CEO, Arsanis
Moderator: Bernat OlleCEO, Vedanta Biosciences

3:50-4:20 pm

Breakthroughs in Infectious Disease Programs
Oreola Donini, CSO, Soligenix; David Huang, CMO, MotifBio; Roelof Rongen, CEO, Matinas Biopharma; Vu TruongCEO, Aridis

4:20-4:50 pm

Industry Outlook: The Next 5 Years
Rahul DhandaSVP, T2 Biosystems; Rasmus Toft-Kehler, CEO & Co-Founder, AntibioTx

4:50-6:00 pm

Cocktails and Hors d'oeuvres

Premier Sponsors: (see all sponsors)

<